Randomised clinical trial: vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis

• DOI: 10.1111/apt.13461
• Publication Date: 2015-11-12T02:01:00Z
• Authors: K. Ashida; Y. Sakurai; T. Hori; K. Kudou; A. Nishimura; N. Hiramatsu; E. Umegaki; K. Iwakiri
• Keywords: Lansoprazole; Clinical endpoint

Summary Background Vonoprazan is a novel potassium‐competitive acid blocker which may provide clinical benefit in acid‐related disorders. Aim To verify the non‐inferiority of vonoprazan vs. lansoprazole patients with erosive oesophagitis ( EE ), and to establish its long‐term safety efficacy as maintenance therapy. Methods In this multicentre, randomised, double‐blind, parallel‐group comparison study, endoscopically confirmed LA Classification Grades A–D) were randomly allocated receive 20 mg or 30 once daily after breakfast. The primary endpoint was proportion healed by endoscopy up week 8. addition, subjects who achieved study re‐randomised into investigate 10 therapy for 52 weeks. Results Of 409 eligible 401 completed 305 entered study. 8 99.0% (203/205) 95.5% (190/199), thus verifying P < 0.0001). also effective more severe C/D) CYP 2C19 extensive metabolisers. there few recurrences (<10%) treated mg. Overall, well‐tolerated. Conclusions verified well‐tolerated during